Agenus. Earnings Calls

Q4 2024 (Upcoming)
Release date Mar 13, 2025
EPS estimate -$2.36
EPS actual -
Revenue estimate 30.094M
Revenue actual -
Expected change +/- 12.07%
Q3 2024 Missed
-$3.17 (-50.95%)
Release date Nov 12, 2024
EPS estimate -$2.10
EPS actual -$3.17
EPS Surprise -50.95%
Revenue estimate 31.81M
Revenue actual 25.112M
Revenue Surprise -21.06%
Q2 2024 Missed
-$2.52 (-89.47%)
Release date Aug 08, 2024
EPS estimate -$1.33
EPS actual -$2.52
EPS Surprise -89.47%
Revenue estimate 61.48M
Revenue actual 23.509M
Revenue Surprise -61.76%
Q1 2024 Beat
-$3.04 (15.08%)
Release date May 07, 2024
EPS estimate -$3.58
EPS actual -$3.04
EPS Surprise 15.08%
Revenue estimate 39.27M
Revenue actual 28.005M
Revenue Surprise -28.69%

Last 4 Quarters for Agenus.

Below you can see how AGEN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Beat
Release date May 07, 2024
Fiscal end date Mar 31, 2024
Price on release $12.01
EPS estimate -$3.58
EPS actual -$3.04
EPS surprise 15.08%
Date Price
May 01, 2024 $13.26
May 02, 2024 $12.52
May 03, 2024 $13.07
May 06, 2024 $12.95
May 07, 2024 $12.01
May 08, 2024 $11.47
May 09, 2024 $11.72
May 10, 2024 $10.49
May 13, 2024 $11.09
4 days before -9.43%
4 days after -7.66%
On release day -4.50%
Change in period -16.37%
Q2 2024 Missed
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $5.28
EPS estimate -$1.33
EPS actual -$2.52
EPS surprise -89.47%
Date Price
Aug 02, 2024 $5.63
Aug 05, 2024 $5.24
Aug 06, 2024 $5.43
Aug 07, 2024 $5.08
Aug 08, 2024 $5.28
Aug 09, 2024 $5.09
Aug 12, 2024 $5.13
Aug 13, 2024 $4.71
Aug 14, 2024 $4.58
4 days before -6.22%
4 days after -13.26%
On release day -3.60%
Change in period -18.65%
Q3 2024 Missed
Release date Nov 12, 2024
Fiscal end date Sep 30, 2024
Price on release $3.11
EPS estimate -$2.10
EPS actual -$3.17
EPS surprise -50.95%
Date Price
Nov 06, 2024 $4.22
Nov 07, 2024 $3.93
Nov 08, 2024 $3.91
Nov 11, 2024 $3.90
Nov 12, 2024 $3.11
Nov 13, 2024 $3.03
Nov 14, 2024 $2.77
Nov 15, 2024 $2.72
Nov 18, 2024 $2.63
4 days before -26.42%
4 days after -15.30%
On release day -2.42%
Change in period -37.68%
Q4 2024 (Upcoming)
Release date Mar 13, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$2.36
EPS actual -
Date Price
Feb 07, 2025 $3.50
Feb 10, 2025 $3.23
Feb 11, 2025 $3.21
Feb 12, 2025 $3.46
Feb 13, 2025 $3.50

Agenus. Earnings Call Transcript Summary of Q3 2024

  • Focus: Agenus is developing BOT/BAL, a novel cancer treatment, showing promising results in previously resistant cancer types.
  • Clinical Developments:
  • BOT/BAL Progress: The drug has demonstrated significant outcomes in microsatellite stable (MSS) colorectal cancer, which accounts for over 85% of colorectal cancer cases, traditionally resistant to immunotherapy. Initial data was presented at ESMO GI 2024.
  • Neoadjuvant Studies: Ongoing trials in Italy and the Netherlands are expected to provide further promising data early next year, expanding the relevance of BOT/BAL beyond colorectal cancer to other difficult-to-treat cancers.
  • Financial Position:
  • Cash Reserves: Agenus ended Q3 2024 with $44.8 million in cash, down from $76.1 million at the beginning of the year but has since raised an additional $7 million.
  • Operational Costs: Cash used in operations dropped from $183.8 million in the first nine months of 2023 to $129.7 million in the same period in 2024, indicating improved financial discipline.
  • Revenue Recognition: Reported revenue includes $25 million in Q3 and $77 million for the first nine months of 2024, primarily non-cash revenue.
  • Strategic Initiatives:
  • Cost Management: Measures are being implemented to reduce expenditures, internalizing various functions like CRO and CDMO services as trials mature.
  • Asset Monetization: The company is looking to monetize real estate assets valued at over $70 million, which may provide financial relief.
  • Strategic Transactions: Agenus is in advanced discussions for potential strategic partnerships to support BOT/BAL's development and ensure long-term growth.
  • Clinical Data and Future Expectations:
  • Phased Study Design: The company has received guidance from the FDA and EMA regarding the design of a Phase 3 study, contingent on securing a strategic partnership to finance the study.
  • Future Presentations: Data from various trials across multiple tumor types, including colorectal cancer, melanoma, and pancreatic cancer, are expected in early 2025.
  • Investor Outlook:
  • Agenus believes that the advancements in BOT/BAL represent a significant opportunity to redefine cancer treatment, potentially leading to improved patient outcomes and quality of life.
  • The management emphasizes their commitment to overcoming financial challenges while pursuing essential strategic initiatives to maintain clinical momentum.
  • Conclusion: Agenus is actively working to address financial constraints while focusing on advancing BOT/BAL through various strategic initiatives, with strong upcoming clinical data expected to enhance investor confidence and stakeholder engagement.
  • Agenus. Earnings History

    Earnings Calendar

    FAQ

    When is the earnings report for AGEN?
    Agenus Inc. (AGEN) has scheduled its earnings report for Mar 13, 2025 before the markets open.

    What is the AGEN price-to-earnings (P/E) ratio?
    AGEN P/E ratio as of Feb 13, 2025 (TTM) is -0.328.

    What is the AGEN EPS forecast?
    The forecasted EPS (Earnings Per Share) for Agenus Inc. (AGEN) for the first fiscal quarter 2024 is -$2.36.

    What are Agenus Inc.'s retained earnings?
    On its balance sheet, Agenus Inc. reported retained earnings of $25.11 million for the latest quarter ending Sep 30, 2024.

    What Is an Earnings Report?
    An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

    Earnings Report Content
    Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

    What To Know About Earnings Reports?
    Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
    Click to get the best stock tips daily for free!
    ABOUT AGENUS INC.
    Agenus.
    Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The...
    GOLDEN STAR
    Ticker Change Signal Date
    IBN
    $29.02
    0.448% Feb 11
    HCP
    $34.11
    0.733% Feb 11
    VRNT
    $26.02
    0.92% Feb 11
    BSY
    $46.63
    0.172% Feb 11
    LFUS
    $234.72
    5.50% Feb 10

    Top Fintech Company

    StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

    Full report by FINDEXABLE